<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>PROFORMA INVOICE</title></head><body><div><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">              </span></p><p style="margin:0pt; text-align:center"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">BioIndustry</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> Association (BIA)</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (AMR0026)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">About the BIA</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">BioIndustry</span><span style="font-family:'Times New Roman'; font-size:11pt"> Association (BIA) is the trade association for innovative bioscience companies. The majority of our members are healthcare focused companies researching and developing new products and technologies to treat areas of unmet medical need. These range from large global biopharmaceuticals to small, pre-revenue companies operating at the translation interface between academia and industry. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The BIA has engaged with its membership in order to provide an informed response to this inquiry. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">The BIA response </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The BIA welcomes the opportunity to respond to this important inquiry into Antimicrobial Resistance (AMR). Comments have been focused in areas in which we feel best able to add value and insight to this inquiry and relate primarily to the environment for the research and development of new antibiotics. This relates primarily to question three of this inquiry’s call for evidence, with some comments relevant also to question six. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The importance of AMR has been well articulated by the Chief Medical Officer Professor Dame Sally Davies. Much of the current focus and action regarding this topic flows from the personal drive and call to action made by Dame Sally Davies. The AMR agenda has greatly benefited from the Chief Medical Officer’s direct involvement and the BIA applauds Dame Sally Davies for this. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The severity of AMR and the challenges it poses have been well articulated by others</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt"> and neatly characterised in the call for evidence to this inquiry. Further description of the problem in this response is therefore not required beyond reinforcing that modern medical practice relies on the widespread availability of effective antimicrobials to prevent and treat infections in humans and animals. The rapid development of bacterial resistance to antibiotics is of particular concern. Continued growth in the number of hard to treat infections will make it increasingly difficult to control infection in a range of routine medical care settings. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A report of April 2013</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt"> identified 109 antibiotics in the development pipeline. Approximately 70% of these are in early development (Preclinical and Phase I), with nine candidates at Phase III, and 31 at Phase II. These developments are being progressed by 66 companies, of which 86% are Small and Medium Sized Enterprises (SMEs). With SMEs being the most active in this space, incentivising SMEs to further research and develop new antibiotics and supporting their engagement with larger biopharmaceutical companies is clearly important. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">With this last point in mind, the Committee may be aware of a recent significant deal which demonstrates the partnerships and collaborations required between SMEs and large companies, with the former undertaking initial research and development work. It was announced on 5 November that Swiss based </span><span style="font-family:'Times New Roman'; font-size:11pt">Polyphor</span><span style="font-family:'Times New Roman'; font-size:11pt"> out-licensed its antibiotic programme to Roche in a deal worth potentially $510 million in up-front and milestone payments</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt">. The lead </span><span style="font-family:'Times New Roman'; font-size:11pt">product in this programme recently entered a Phase II trial. Roche is the owner of two prominent antibiotics (</span><span style="font-family:'Times New Roman'; font-size:11pt">Roceptin</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">Bactrim</span><span style="font-family:'Times New Roman'; font-size:11pt">) but this represents a significant development. It has been reported that recent regulatory enhancements and other incentives towards antibiotic development has influenced this decision.  </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Against this backdrop, the government’s Five Year Antimicrobial Resistance Strategy 2013 to 2018 provides a useful focal point</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Times New Roman'; font-size:11pt">. In particular, its third strategic aim – to stimulate the development of new antibiotics, diagnostics and novel therapies – is particularly important to ensure the proper incentives are in place for innovative new products. This is the area where BIA members and the wider innovative bioscience community are most able to contribute. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK AMR Strategy’s three strategic aims, underpinned by actions in seven key areas, provide a fairly comprehensive list of the focus areas. However, they will also need to be matched by specific actions, particularly in the area of </span><span style="font-family:'Times New Roman'; font-size:11pt">incentivisation</span><span style="font-family:'Times New Roman'; font-size:11pt">, to ensure new antibiotics are developed.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There have been a number of proposals regarding how to incentivise the commercial research and development of a new class of antibiotics, including lengthening the periods of exclusivity afforded to products once they have reached market through extended regulatory data protection for example. Similar provisions afforded to orphan products have demonstrably helped to increase the number of new medicines to treat rare diseases.  </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are also recommendations regarding enhancements to the regulatory framework. It is hoped such enhancements might reduce the length of time it takes to develop new antibiotics whilst retaining the highest standards of safety and efficacy, thus reducing the cost of development. In 2012 the US Congress approved the Generating Antibiotic Incentives Now Act</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt"> which provides for five years of additional market exclusivity for qualified antibiotics as well as providing fast track regulatory review at the FDA. It also led to the establishment of a new FDA task force to support innovation in antibacterial drug development</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:'Times New Roman'; font-size:11pt">.   </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In the UK, the MHRA’s newly established Innovation Office may play a similar role. Additionally, innovative new antibiotics may be suitable for the proposed Earlier Access to medicines Scheme should one be established by the government</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a><span style="font-family:'Times New Roman'; font-size:11pt">. Such a scheme might allow for earlier patient access to innovative new treatments, in an unlicensed setting and outside of a clinical trial, should the medicine be innovative, for an area of unmet medical need, and demonstrating a positive safety and efficacy profile, amongst other reasons, for example. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">If the Earlier Access to medicines Scheme allowed for earlier reimbursement it could provide further </span><span style="font-family:'Times New Roman'; font-size:11pt">incentivisation</span><span style="font-family:'Times New Roman'; font-size:11pt"> to research and develop new antibiotics. The BIA continues to call for the introduction of this scheme, with adequate reimbursement, and responded as such to the government consultation which finished in September 2012. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Enhancements to the regulatory and intellectual property framework, amongst other areas, may be suitable </span><span style="font-family:'Times New Roman'; font-size:11pt">incentivisations</span><span style="font-family:'Times New Roman'; font-size:11pt"> to antibiotic research and are worth pursuing. However, at the earlier stages, the </span><span style="font-family:'Times New Roman'; font-size:11pt">incentivisation</span><span style="font-family:'Times New Roman'; font-size:11pt"> of SMEs to translate promising antibiotic research will rely on the funding and fiscal landscape. This is particularly important given that SMEs are responsible for a large number of the products currently under development (as outlined above). This response will therefore provide some detailed comment on such issues below. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is also worth stressing, before outlining the funding and fiscal landscape, that the UK does have leading commercial organisations operating in the research and development of new antibiotics, varying from global multi-national pharmaceutical companies such as AstraZeneca to small pre-revenue university spin-outs in their first years of operation. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For example, </span><span style="font-family:'Times New Roman'; font-size:11pt">Redx</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Pharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> has created a new venture, </span><span style="font-family:'Times New Roman'; font-size:11pt">Redx</span><span style="font-family:'Times New Roman'; font-size:11pt"> Anti-</span><span style="font-family:'Times New Roman'; font-size:11pt">Infectives</span><span style="font-family:'Times New Roman'; font-size:11pt"> Ltd</span><a name="_ftnref8"></a><a href="#_ftn8">[8]</a><span style="font-family:'Times New Roman'; font-size:11pt">, with the creation of 119 new science jobs at the AstraZeneca </span><span style="font-family:'Times New Roman'; font-size:11pt">Alderley</span><span style="font-family:'Times New Roman'; font-size:11pt"> Park site in Cheshire to develop drugs to combat resistance to antibiotics and new medicines to tackle viral infections, including the threat of drug resistant ‘superbugs’ like MRSA. This activity has been supported by a grant of £4.7 million from the Regional Growth Fund</span><a name="_ftnref9"></a><a href="#_ftn9">[9]</a><span style="font-family:'Times New Roman'; font-size:11pt"> alongside significant private investment.  </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Industry, academia, the public sector and others are taking an active role in discussing the issue seeking to improve collaboration and address challenges. An upcoming conference organised by </span><span style="font-family:'Times New Roman'; font-size:11pt">Bionow</span><span style="font-family:'Times New Roman'; font-size:11pt">, named </span><span style="font-family:'Times New Roman'; font-size:11pt">Bioinfect</span><a name="_ftnref10"></a><a href="#_ftn10">[10]</a><span style="font-family:'Times New Roman'; font-size:11pt">, is testament to this. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Fiscal environment</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt"> The research and development of new medicines is an expensive and risky exercise. Accounting for product failures, it can cost, on average, around £1bn to £1.2bn to develop a single new medicine, taking, on average, ten to fifteen years. Pre-revenue equity-backed SMEs are increasingly the source of innovative new potential medicines and act at the translational interface between academia and industry. The research and development of medicines is increasingly a collaborative activity and the development of new early stage candidates by SMEs is an important part of this process. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The environment for private equity investment, traditionally Angel investment at an early stage and Venture Capital at a later stage, remains challenging, although a recent BIA / EY report has shown the UK leads Europe in ‘innovation capital’ raised.</span><a name="_ftnref11"></a><a href="#_ftn11">[11]</a></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Companies seeking to develop new antibiotic candidates operate within this same constrained funding environment. However, in many cases it can be argued that seeking funding for antibiotics is made even more challenging given it is more difficult to recoup investment for antibiotic development as compared to other drugs, for chronic illnesses for example. This is because, by their design, antibiotics are intended to be used sparingly. The challenges faced by all companies in this sector are therefore accentuated in antibiotic development. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">This makes the need for a tax framework that encourages such innovation even more important. The UK continues to develop such a competitive tax framework through R&amp;D tax credits and the introduction of the patent box, for example. These are important instruments that rightly seek to support continued research and development in the UK. While further enhancements can be made, the BIA / EY report</span><a name="_ftnref12"></a><a href="#_ftn12">[12]</a><span style="font-family:'Times New Roman'; font-size:11pt"> demonstrated that the UK has arguably the most competitive tax environment for entrepreneurial businesses. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Grant funding and other public support</span><span style="font-family:'Times New Roman'; font-size:11pt">: BIA members have been consistent in their view that non-dilutive grants are a vital source of capital for innovative SMEs. These enable them to more easily attract additional private finance, particularly at an early stage, for example before the generation of Phase II clinical trial data, before larger amounts of private capital may be raised or partnership opportunities explored. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Such public funding demonstrably supports the research and development of new products and technologies in the UK, and in particular the Biomedical Catalyst</span><a name="_ftnref13"></a><a href="#_ftn13">[13]</a><span style="font-family:'Times New Roman'; font-size:11pt"> is responsible for much of the positive upswing in private investment over the last 12 to 18 months. Over 100 business-led projects, 25% of which are collaborative involving one or more organisations, across a wide range of therapeutic areas, have leveraged almost £70 million of additional private finance into the UK.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As well as providing public funding, which must be matched by private capital, the Biomedical Catalyst also provides a level of ‘endorsement’ or a ‘stamp of approval’ for a research project, given the rigorous scrutiny applications are subject to and the highly competitive nature of the fund. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Biomedical Catalyst has been transformative for the sector and its importance to this inquiry relates to the large number of antibiotic and anti-infective research projects it is supporting. It shows there is such research underway in the UK and also shows the importance of non-dilutive grants to support it. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Innovative new approaches are being funded, including Blueberry Therapeutics Ltd developing a new class of bacterial resistance inhibitors for the treatment of multi-drug resistant infection, </span><span style="font-family:'Times New Roman'; font-size:11pt">Abysnth</span><span style="font-family:'Times New Roman'; font-size:11pt"> Biologics Ltd developing a novel effective vaccine for </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">aureus</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections and </span><span style="font-family:'Times New Roman'; font-size:11pt">Cantab</span><span style="font-family:'Times New Roman'; font-size:11pt"> Biopharmaceuticals Ltd seeking to address multi-drug resistant (MDR) Gram negative bacterial infections. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Technology Strategy Board, through the Biomedical Catalyst and other funding streams, has shown itself to be a valuable UK asset in supporting medical research. Other UK departments could learn from the approach taken to the funding call, the assessment process and the distribution of funds. Lessons can also be learnt from other countries, particularly regarding the role of Defence Ministries. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="26" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is understood that the UK Ministry of Defence does periodically open funding calls related to novel antimicrobial approaches but BIA members involved in this field suggest larger scale and more flexible calls might be effective, and point to examples in France and the United States. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="27" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For example, </span><span style="font-family:'Times New Roman'; font-size:11pt">Pherecydes</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Pharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> has secured a €900,000 funding grant from the French Government Defence procurement agency towards a €1.2 million project evaluating the use of </span><span style="font-family:'Times New Roman'; font-size:11pt">bacteriophages</span><span style="font-family:'Times New Roman'; font-size:11pt"> against infected, antibiotic resistant burns</span><a name="_ftnref14"></a><a href="#_ftn14">[14]</a><span style="font-family:'Times New Roman'; font-size:11pt">. The funds fall within the framework of the RAPID programme which supports dual innovation by SMEs through providing financial support for projects that have commercial potential, are innovative and have both military and civilian applications. The project also includes the Institute of Genetics and Microbiology of the University of Paris and the Armed Forces Institute of Biomedical Research. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="28" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The US military also appear to be taking </span><span style="font-family:'Times New Roman'; font-size:11pt">bacteriophage</span><span style="font-family:'Times New Roman'; font-size:11pt"> therapy seriously as a means of augmenting the role antibiotics play in pathogen control, as seen by the agreement signed between </span><span style="font-family:'Times New Roman'; font-size:11pt">AmpliPhi</span><span style="font-family:'Times New Roman'; font-size:11pt"> Biosciences, which has a UK presence, and the US Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research, to develop such therapies for drug resistant infections</span><a name="_ftnref15"></a><a href="#_ftn15">[15]</a><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="29" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Perhaps the UK might consider the use of such funding streams more directly targeted towards the AMR threat. The TSB’s Small Business Research Initiative (SBRI) exists for such procurement activities but to date has not been readily taken up in this area, often because the development timeline for new medicines does not lend itself to a rigid procurement structure. With additional funding now being channelled through the SBRI schemes this might offer one route to significantly support new antimicrobial development. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Appendix</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The below table lists brief details of some of the business-led projects which have been awarded Biomedical Catalyst funding, following an application process and subject to conditions, which relate to the development of new antibiotics, anti-</span><span style="font-family:'Times New Roman'; font-size:11pt">infectives</span><span style="font-family:'Times New Roman'; font-size:11pt"> and other research of relevance to the issue of AMR. These are projects across all application stages (feasibility, early stage and late stage) and from funding rounds one, two and three. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%"><tr style="height:75.75pt"><td style="background-color:#bfbfbf; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Company</span></p></td><td style="background-color:#bfbfbf; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Grant amount</span></p></td><td style="background-color:#bfbfbf; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Project cost</span></p></td><td style="background-color:#bfbfbf; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Project duration (months)</span></p></td><td style="background-color:#bfbfbf; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Brief description</span></p></td></tr><tr style="height:57.75pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Absynth</span><span style="font-family:'Times New Roman'; font-size:11pt"> Biologics Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£150,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£201,103</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Building a product pipeline – establishing the commercial potential of new products [innovative approaches to antibacterial vaccines] </span></p></td></tr><tr style="height:29.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Absynth</span><span style="font-family:'Times New Roman'; font-size:11pt"> Biologics Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£2,013,706</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£3,049,019</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">36</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">aureus</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections - development of a novel, effective vaccine</span></p></td></tr><tr style="height:43.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Ai2 Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£150,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£205,491</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Assessing the feasibility of developing Ai2's novel anti-infective peptide technology for topical anti-fungal applications</span></p></td></tr><tr style="height:29.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Applied </span><span style="font-family:'Times New Roman'; font-size:11pt">Nanodetectors</span><span style="font-family:'Times New Roman'; font-size:11pt"> Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£149,709</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£199,612</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Point of care exhaled breath test for the diagnosis of community acquired pneumonia</span></p></td></tr><tr style="height:30pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Base4 Innovation Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£2,250,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£7,214,060</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">36</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">A rapid, highly sensitive, adaptable diagnostic for broad spectrum pathogen screening</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr style="height:44.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Blueberry Therapeutics Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£150,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£213,944</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Development of a new class of bacterial resistance inhibitors for the treatment of multi-drug resistant infection</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr style="height:43.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Cantab</span><span style="font-family:'Times New Roman'; font-size:11pt"> Biopharmaceuticals Limited</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£2,321,884</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£3,869,807</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">30</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Addressing multi-drug resistant (MDR) Gram-negative bacterial infections by enhanced antibiotic uptake</span></p></td></tr><tr style="height:29.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Discuva</span><span style="font-family:'Times New Roman'; font-size:11pt"> Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£1,620,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£2,700,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">24</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Discovery of new, commercially valuable antibiotics to treat bacterial infections</span></p></td></tr><tr style="height:29.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">ELISHA Systems Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£358,956</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£717,956</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">30</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Phage </span><span style="font-family:'Times New Roman'; font-size:11pt">lysin</span><span style="font-family:'Times New Roman'; font-size:11pt"> biosensor detection of MRSA: point of care prototype: PROMPT-Plus</span></p></td></tr><tr style="height:57.75pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Enigma Diagnostics Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£148,338</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£197,785</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Resonant sensing, a novel form of DNA detection for low-cost highly informative tests; construction of an assay for multidrug resistant TB and bovine TB</span></p></td></tr><tr style="height:29.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Indigix</span><span style="font-family:'Times New Roman'; font-size:11pt"> Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£150,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£200,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dendrimer</span><span style="font-family:'Times New Roman'; font-size:11pt"> based drug for life threatening infectious diarrhoeal diseases</span></p></td></tr><tr style="height:29.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">MicroPharm</span><span style="font-family:'Times New Roman'; font-size:11pt"> Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£2,067,535</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£2,599,535</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">36</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Use of ovine polyclonal antibodies to treat severe </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Clostridium </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections</span></p></td></tr><tr style="height:43.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">ProteinLogic</span><span style="font-family:'Times New Roman'; font-size:11pt"> Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£76,922</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£102,562</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Feasibility of developing a novel biomarker signature as an innovative diagnostic for tuberculosis (TB)</span></p></td></tr><tr style="height:29.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Union Life Sciences Ltd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£150,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£262,936</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Novel inhibitors for the treatment of infectious disease</span></p></td></tr><tr style="height:29.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:25.56%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Valevia</span><span style="font-family:'Times New Roman'; font-size:11pt"> UK</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£150,000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">£204,353</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.84%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">10</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:41.9%"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">A novel agent for the treatment of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> infection</span></p></td></tr></table><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Arial; font-size:6pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Arial; font-size:10pt"> </span><span style="font-family:Arial; font-size:10pt">A recent POST note provides a succinct overview for example: </span><a href="http://www.parliament.uk/briefing-papers/POST-PN-446.pdf"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.parliament.uk/briefing-papers/POST-PN-446.pdf</span></a><span style="font-family:Arial; font-size:10pt"> </span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Arial; font-size:10pt"> Antibiotics Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance, </span><a href="http://cid.oxfordjournals.org/content/early/2013/04/16/cid.cit152.full"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://cid.oxfordjournals.org/content/early/2013/04/16/cid.cit152.full</span></a><span style="font-family:Arial; font-size:10pt"> </span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.roche.com/media/media_releases/med-cor-2013-11-04.htm"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.roche.com/media/media_releases/med-cor-2013-11-04.htm</span></a></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf</span></a></p><p style="margin:0pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.battlingsuperbugs.com/gain-act.html"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.battlingsuperbugs.com/gain-act.html</span></a><span style="font-family:Arial; font-size:10pt"> </span></p><p style="margin:0pt"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm</span></a><span style="font-family:Arial; font-size:10pt"> </span></p><p style="margin:0pt"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="font-family:Arial; font-size:10pt"> This proposal was contained within the Strategy for UK Life Sciences.</span></p><p style="margin:0pt"><a name="_ftn8"></a><a href="#_ftnref8">[8]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.redxpharma.com/about-us-subsidiaries-redx-anti-infectives.php"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.redxpharma.com/about-us-subsidiaries-redx-anti-infectives.php</span></a></p><p style="margin:0pt"><a name="_ftn9"></a><a href="#_ftnref9">[9]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.redxpharma.com/news-article-20130507.php?filter=Show_All"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.redxpharma.com/news-article-20130507.php?filter=Show_All</span></a></p><p style="margin:0pt"><a name="_ftn10"></a><a href="#_ftnref10">[10]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.bionow.co.uk/events/bioinfect2013.aspx"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.bionow.co.uk/events/bioinfect2013.aspx</span></a></p><p style="margin:0pt"><a name="_ftn11"></a><a href="#_ftnref11">[11]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.bioindustry.org/document-library/bia-ey-state-of-the-nation-report/"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.bioindustry.org/document-library/bia-ey-state-of-the-nation-report/</span></a></p><p style="margin:0pt"><a name="_ftn12"></a><a href="#_ftnref12">[12]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.bioindustry.org/document-library/bia-ey-state-of-the-nation-report/"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.bioindustry.org/document-library/bia-ey-state-of-the-nation-report/</span></a></p><p style="margin:0pt"><a name="_ftn13"></a><a href="#_ftnref13">[13]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.bioindustry.org/policy-and-regulation/biomedical-catalyst/"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.bioindustry.org/policy-and-regulation/biomedical-catalyst/</span></a></p><p style="margin:0pt"><a name="_ftn14"></a><a href="#_ftnref14">[14]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.pherecydes-pharma.com/files/120118%20DGA%20Pherecydes%20ENG.pdf"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.pherecydes-pharma.com/files/120118%20DGA%20Pherecydes%20ENG.pdf</span></a></p><p style="margin:0pt"><a name="_ftn15"></a><a href="#_ftnref15">[15]</a><span style="font-family:Arial; font-size:10pt"> </span><a href="http://www.ampliphibio.com/news/47-ampliphi-signs-global-r-d-agreement-with-us-army-to-develop-bacteriophage-therapies-to-treat-resistant-bacterial-infections.html"><span style="color:#0000ff; font-family:Arial; font-size:10pt; text-decoration:underline">http://www.ampliphibio.com/news/47-ampliphi-signs-global-r-d-agreement-with-us-army-to-develop-bacteriophage-therapies-to-treat-resistant-bacterial-infections.html</span></a></p></body></html>